Non-Clinical Performance Assessment of Tissue Containment Systems Used During Power Morcellation Procedures

June 21, 2022

June 2022

Draft Guidance for Industry and Food and Drug Administration Staff

Introduction

This draft guidance document provides recommendations that may help manufacturers comply with the special controls related to non-clinical performance data for gynecologic and general laparoscopic power morcellation containment systems (“tissue containment systems”). Tissue containment systems are used to enable isolation and containment of tissue during a power morcellation procedure performed following a laparoscopic procedure for the excision of benign tissue that is not suspected to contain malignancy. These devices are class II (special controls) and subject to premarket notification (510(k)) requirements. Throughout this guidance, the terms “FDA,” “the Agency,” “we,” and “us” refer to the Food and Drug Administration and the terms “you” and “yours” refer to medical device manufacturers. For the current edition of the FDA-recognized consensus standard(s) referenced in this document, see the FDA Recognized Consensus Standards Database. For more information regarding use of consensus standards in regulatory submissions, please refer to the FDA 102 guidance titled “Appropriate Use of Voluntary Consensus Standards in Premarket Submissions for Medical Devices.”

Download the Draft Guidance Document

Draft

Read the Federal Register Notice

Not for implementation. Contains non-binding recommendations.

This guidance is being distributed for comment purposes only.

Interested in learning more? Contact us today to find out how we can help not only with your EMA/FDA submissions, but all of your global regulatory needs.




FDA North America

June 21, 2022

FDA Draft Guidance for Industry, Evaluation of Therapeutic Equivalence

FDA Draft Guidance July, 2022 As part of the FDA’s continued efforts to provide helpful information to regulated industry and the public, the agency has published a draft guidance for industry,...

Read More
FDA North America

June 21, 2022

FDA revises 2013 guidance - Non-Penicillin Beta-Lactam Drugs: A CGMP Framework for Preventing Cross-Contamination

Draft Guidance June 2022 FDA is announcing the availability of a draft guidance titled, "Non-Penicillin Beta-Lactam Drugs:  A CGMP Framework for Preventing Cross-Contamination." This guidance revises...

Read More
FDA North America

June 21, 2022

FDA Issues Draft Guidance for Industry, Considerations for Rescinding Breakthrough Therapy Designation

Draft Guidance June 24, 2022 The U.S. Food and Drug Administration issued a draft guidance for industry titled Considerations for Rescinding Breakthrough Therapy Designation. This draft guidance...

Read More